Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Liabilities and Shareholders Equity (2020 - 2025)

Barinthus Biotherapeutics' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $98.2 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 38.77% year-over-year to $98.2 million; the TTM value through Dec 2025 reached $478.9 million, down 34.86%, while the annual FY2025 figure was $98.2 million, 38.77% down from the prior year.
  • Liabilities and Shareholders Equity reached $98.2 million in Q4 2025 per BRNS's latest filing, down from $109.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $286.1 million in Q1 2022 to a low of $98.2 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $212.4 million, with a median of $222.2 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 454.05% in 2021, then tumbled 42.13% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $280.7 million in 2021, then fell by 3.74% to $270.2 million in 2022, then fell by 20.61% to $214.5 million in 2023, then fell by 25.26% to $160.3 million in 2024, then plummeted by 38.77% to $98.2 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Liabilities and Shareholders Equity are $98.2 million (Q4 2025), $109.2 million (Q3 2025), and $129.6 million (Q2 2025).